alexa Detection Of Janus Kinase 2 (JAK2V617F) In Sudanese Patients With Polycythemia In Khartoum State, Sudan
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

10th International Conference on CANCER STEM CELLS AND ONCOLOGY RESEARCH
June 26-28, 2017 London, UK

Mouhanad Adam
Alzaiem Alazhari University, Sudan
Posters & Accepted Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956-C1-103
Background & Aim: Erythrocytosis is form of hematological diseases, the main members of which are polycythemia vera (PV) , familial polycythemia and idiopathic erythrocytosis. The molecular pathogenesis of these disorders is unknown, but tyrosine kinases have been implicated in several related disorders. We investigated the presence of the cytoplasmic tyrosine kinase JAK2 in patients with polycythemia and the hematological difference between these types in Sudanese patients. Methods: We measure the full blood counts and obtained DNA samples from patients with erythrocytosis. The JAK2V617F mutation was detected from peripheral-blood samples. Allele-specific PCR were undertaken on subgroups of patients who satisfied the WHO criteria of polycythemia vera. Results: A single point mutation (V617F) was identified in JAK2 in 31 (54.4%) of 57 patients with polycythemia and there are no significant differences of hemoglobin, hematocrit, and neutrophil between patients with the JAK2 mutation and who without the mutation. Polycythemia vera patients who are not detected for the mutation and patients with idiopathic erythrocytosis showing no difference except in platelet's count . Interpretation: A single mutation of JAK2V617F was noted in more than half of patients with erythrocytosis. If the person is negative for JAK2V617F mutations, the person may still have a PV. The person could have a JAK2 exon 12 mutation which was not detected during research.

Mouhanad Adam has completed his MSc from Alzaiem Alazhari University. He is the Director of Alshamel Clinical Lab. He was awarded a Master’s degree in Hematology and blood transfusion with grade very good. He is very interested in the molecular and hematological studies as general.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version